Consistent with our previous findings, the treatment of tumor-bearing mice with systemic IL-15 prevented NK cell dysfunction and enhanced their antitumor function, as determined by a retardation in tumor growth kinetics, although this effect was also partly driven by the survival and differentiation effects of IL-15 on CD8 + T cells. The gene discussed is CD8A; the disease is neoplasm.